Analyzing the impact of aging on the immune system in the context of covid-19 vaccinatio
- Conditions
- COVID-19
- Registration Number
- JPRN-jRCT1050210014
- Lead Sponsor
- Hamazaki Yoko
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 200
1) Subjects working at Kyoto University and aged 20 years old or older at informed consent with no major medical history and other medical problems
2) Subjects aged 65 years old or older at informed consent with no major medical history
3) Subjects who have obtained written consent voluntarily to participate in this trial
4) Subjects who are scheduled to receive COVID-19 vaccination
1) Subjects who have been administered with drugs that affect the immune system (excluding external preparations) such as immunomodulators (DMARDs, etc.), immunosuppressants, biologics, etc.
2) Subjects who are tested positive for human immunodeficiency virus (HIV), hepatitis C virus (HCV), hepatitis B virus (HBV), or HTLV-1.
3) Subjects who are otherwise ineligible for this study in the principal investigator's or subinvestigator's opinion.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1) Anti-Ig levels in blood <br>2) T-cell response in peripheral blood<br>3) Phenotypes of immune cells in peripheral blood
- Secondary Outcome Measures
Name Time Method